Skip to main content
. 2013 Jan;6(1):19–33. doi: 10.1177/1756285612461679

Table 2.

Disease-modifying treatments: modulation of tau deposition.

Interfering with tau deposition Interfering with tau phosphorylation Immunotherapy
Methylene blue: phase II trial (+) Tau kinase inhibitors (lithium: phase I trial () in AD (+) in MCI ) Vaccination: preclinical trials
+

, encouraging results; −, disappointing results.

AD, Alzheimer’s disease; MCI, mild cognitive impairment.1